Printer Friendly

SYNCOR ANNOUNCES RECORD THIRD QUARTER AND NINE MONTH RESULTS

 SYNCOR ANNOUNCES RECORD THIRD QUARTER AND NINE MONTH RESULTS
 CHATSWORTH, Calif., March 24 /PRNewswire/ -- Syncor International Corporation (NASDAQ: SCOR) announced today record sales and earnings for the third quarter and the nine month period ended Feb. 29, 1992. This is the 11th consecutive quarter that the company has achieved record growth.
 Sales for the third quarter of fiscal 1992 increased 39 percent to $53.3 million, up from $38.3 million in the third quarter of fiscal 1991. Sales for the nine month period ended Feb. 29, 1992, increased 35 percent to $151.2 million, as compared to $111.7 million for the corresponding period of the prior year. Net income for the third quarter of fiscal 1992 increased 65 percent to $1.3 million or $.12 per share compared to $0.8 million or $.08 per share for fiscal 1991. Net income for the nine months ended Feb. 29, 1992, increased 54 percent to $4.5 million or $.41 per share, up from $2.9 million or $.28 per share for the same period of fiscal 1991.
 Commenting on the results, Gene McGrevin, Syncor's president and chief executive officer stated, "Our outstanding sales and earnings continue to be driven by the cardiology business, specifically the successful introduction of three new products in fiscal 1992 including, DuPont Merck's 'Cardiolite(R)' and 'I.V. Persantine(R)' (manufactured and distributed by DuPont Merck under license from Boehringer Ingleheim Pharmaceuticals), and Squibb Diagnostic's CardioTech(R). We expect the market penetration of these products will continue, although at a somewhat reduced rate. Management's focus remains on the expansion of Syncor's infrastructure in order to support the introduction of products currently in the pipeline, and the further development of our National Pharmacy Service Network."
 Syncor International operates a nationwide network of 92 nuclear pharmacy service centers and 14 home infusion pharmacies. The company prepares and delivers patient-specific intravenous drugs and solutions for use in diagnostic imaging and a complete range of products for home infusion therapy. Syncor services over 5,000 hospitals, clinics, physicians' offices, nursing facilities, and home-based patients. The only national pharmacy network of its kind, Syncor is unique in combining diagnostic, therapeutic and monitoring services for both hospitals and alternate-site markets.
 SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
 Consolidated Statements of Operations
 (In thousands, except per share data)
 Three Months Ended 2/29/92 2/28/91
 (Unaudited)
 Net sales $53,328 $38,308
 Cost of sales 35,343 25,423
 Gross profit 17,985 12,885
 Operating, selling, and
 administrative expenses 15,812 11,574
 Operating income 2,173 1,311
 Other income (expense), net 105 48
 Income before taxes 2,278 1,359
 Provision for income taxes 932 542
 Net income 1,346 817
 Net income per share of common stock
 and common stock equivalents $0.12 $0.08
 Weighted average common stock and
 common stock equivalents 10,958 10,358
 Net income per share of common stock
 and common stock equivalents
 assuming full dilution $0.12 $0.08
 Weighted average common stock
 and common stock equivalents
 assuming full dilution 10,958 10,482
 SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
 Consolidated Statements of Operations
 (In thousands, except per share data)
 Nine Months Ended 2/29/92 2/28/91
 (Unaudited)
 Net sales $151,247 $111,654
 Cost of sales 98,685 73,145
 Gross profit 52,562 38,509
 Operating, selling, and
 administrative expenses 45,128 33,571
 Operating income 7,434 4,938
 Other income (expense), net 151 (81)
 Income before taxes 7,585 4,857
 Provision for income taxes 3,110 1,943
 Net income 4,475 2,914
 Net income per share of common stock
 and common stock equivalents $0.41 $0.28
 Weighted average common stock and
 common stock equivalents 10,827 10,295
 Net income per share of common stock
 and common stock equivalents
 assuming full dilution $0.41 $0.28
 Weighted average common stock
 and common stock equivalents
 assuming full dilution 10,866 10,308
 -0- 3/24/92
 /CONTACT: John K. Watkins, controller of Syncor International, 818-886-7400, or Susan Noonan or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Syncor International/
 (SCOR) CO: Syncor International Corporation ST: California IN: MTC SU: ERN


PS -- NY004 -- 0921 03/24/92 09:06 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 24, 1992
Words:706
Previous Article:UTILITIES OPPOSE PROPOSED CONSUMERS POWER SETTLEMENT
Next Article:CAMPBELL INTRODUCES HEALTHY REQUEST (TM) SPAGHETTI SAUCES; SAUCES ADDRESS CONCERNS ABOUT FAT, CHOLESTEROL, SODIUM AND CALORIES
Topics:


Related Articles
SYNCOR ANNOUNCES RECORD SECOND QUARTER, SIX MONTH RESULTS
SYNCOR ANNOUNCES RECORD FOURTH QUARTER AND YEAR END RESULTS
SYNCOR ANNOUNCES RECORD FIRST QUARTER RESULTS
SYNCOR ANNOUNCES RECORD SECOND QUARTER AND SIX MONTH RESULTS
SYNCOR APPOINTS MICHAEL A PIRAINO AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
IMAGING FIRM GOING TO SYNCOR.
SYNCOR WINS MAJOR BUYER : VALLEY FIRM GETS 4-YEAR CONTRACT.
CARDINAL HEALTH NET UP 28% IN 3RD QUARTER.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters